PARK2 CpG Methylation Analysis for Monocyte Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying and quantifying monocytes in complex samples, such as blood or immune cells, are not robust enough and often require purification or enrichment steps, limiting their reliability and convenience.
Innovation Solution
Analyzing the methylation status of specific CpG positions in the PARK2 gene region, particularly using bisulfite convertibility, to differentiate monocytes from other cells without the need for purification, utilizing primers and amplification methods like PCR to quantify monocyte levels based on the ratio of bisulfite convertible to non-convertible DNA.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used to identify and quantify monocytes in complex samples, then monocyte detection can be performed, but the methods lack robustness and require purification or enrichment steps
Solution Approach 1:
The invention changes the detection parameter from protein markers (flow cytometry) or cell morphology (microscopy) to DNA methylation status at specific CpG positions in the PARK2 gene. This epigenetic parameter is unique to monocytes and allows direct detection in complex samples without purification, resolving the contradiction between reliability and complexity
Solution Approach 2:
The invention extracts and analyzes only the specific CpG positions within the PARK2 gene that are differentially methylated in monocytes. By focusing on this specific genetic region rather than analyzing entire genomes or requiring cell isolation, the method achieves high reliability without the need for purification steps
2Measurement precision
If current methods are used to identify monocytes, then monocyte presence can be detected, but the quantification is not precise enough
Solution Approach 1:
The invention replaces manual cell counting and flow cytometry with a molecular biology-based detection system using PCR amplification and methylation-specific assays. This substitution enables precise quantification of monocytes based on DNA methylation levels, achieving high measurement precision while maintaining ease of operation through standardized molecular protocols
Solution Approach 2:
The invention creates a molecular copy or signature of monocyte presence through detection of the specific DNA methylation pattern at PARK2 CpG positions. This epigenetic copy serves as a precise quantitative marker that can be measured without manipulating the actual cells, improving both precision and operational convenience
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for reliable and convenient identification and quantification of monocytes, distinguishing them from other immune cells with high specificity, enabling applications in diagnostics and monitoring of immune-related conditions without the need for cell purification.
Implementation Method 1
analyzing the methylation status of at least one cytosine-phosphodiester-guanine (CpG) position in the mammalian gene region for parkin RBR E3 ubiquitin protein ligase (PARK2), wherein a demethylation or lack of methylation of said gene region is indicative for a monocyte
Data Source
AI summary
The present invention relates to a method, in particular an in vitro method, for identifying monocytes, comprising analyzing the methylation status of at least one CpG position in the mammalian gene region for parkin RBR E3 ubiquitin protein ligase (PARK2), wherein a de-methylation or lack of methylation of said gene region is indicative for a monocyte, when compared to a non-monocyte cell. The analyses according to the invention can identify monocytes on an epigenetic level and distinguish them from all other cells in complex samples, such as, for example, other blood or immune cells. The present invention furthermore provides an improved method for quantifying monocytes, in particular in complex samples. The method can be performed without a step of purifying and/or enriching cells, preferably in whole blood and/or non-trypsinized tissue. Also claimed are kits and specific oligonucleotides for use as primers or probes.